Race and gender differences in the association of Lp(a) with carotid artery wall thickness: The Atherosclerosis Risk in Communities (ARIC) Study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 471-478

  Schreiner, Pamela J ^a   Heiss, Gerardo ^b   Tyroler, H A ^b   Morrisett, Joel D ^d   Davis, C E ^c   Smith, Robert ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e Mississippi Family Health Center   (United States)

Author keywords

atherosclerosis; gender; lipoprotein(a); race

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; B SCAN; CAROTID ARTERY DISEASE; CAUCASIAN; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES;

EID: 0029866911     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.471     Document Type: Article

References (84)

1. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischemic heart disease. Lancet. 1988;1:1070-1073.
2. Hoefler G, Harnoncourt F, Paschke E, Mirti W, Pfeiffer KH, Kostner GM. Lipoprotein (a): a risk factor for myocardial infarction. Arteriosclerosis. 1988;8:398-401.
3. Rhoads GG, Dahlén G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
4. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
5. Jürgens G, Költringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987;37:513-515.
6. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
7. Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942-945.
8. Költringer P, Jürgens G. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis. 1985;58:187-198.
9. Scanu AM. Lipoprotein(a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988;112:1045-1047.
10. Hellsten G, Boman K, Hallmans G, Dahlén G. Lipids and endurance physical activity. Atherosclerosis. 1989;75:93-94.
11. Dufaux B, Order U, Müller R, Hollmann W. Delayed effects of prolonged exercise on serum lipoproteins. Metabolism. 1986;35:105-109.
12. Kervinen K, Savolainen MJ, Kesäniemi YA. A rapid increase in lipoprotein(a) levels after ethanol withdrawal in alcoholic men. Life Sci. 1991;48:2183-2188.
13. Marth E, Cazzolato G, Bittolo Bon G, Avogaro P, Kostner GM. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab. 1982;26:56-62.
14. Jenkins AJ, Steele JS, Janus ED, Best JD. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes. 1991;40:787-790.
15. Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P, Doumith R, Thervet F, DeGennes JL. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA. 1990;263:35-36.
16. Nabulsi A, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
17. Soma M, Fumagalli R, Paoletti R, Meschia M, Maini MC, Crosignani P, Ghanem K, Gaubatz J, Morrisett JD. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet. 1991;337:612. Letter.
18. Sandkamp M, Assmann G. Lipoprotein(a) in PROCAM participants and young myocardial infarction survivors. In: Scanu AM, ed. Lipoprotein(a): 25 Years of Progress. New York, NY: Academic Press; 1990:205-209.
19. Hearn JA, DeMaio SJ Jr, Roubin GS, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol 1990;66:1176-1180.
20. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis. 1986;62:249-257.
21. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
22. Niendorf A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U, Dietel M. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anal. 1990;417:105-111.
23. Gushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989;9:593-603.
24. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-592.
25. Hoff HF, Beck GJ, Skibinski CI, Jürgens G, O'Neil J, Kramer J, Lytle B. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;77:1238-1244.
26. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.
27. Levitsky LL, Scanu AM, Gould SH. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care. 1991;14:283-287.
28. Srinivasan S, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children: Bogalusa Heart Study. Circulation. 1991;84:160-167.
29. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
30. Parra H-J, Luyéyé I, Bouramoué C, Demarquilly C, Fruchart J-C. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;167:27-31.
31. Guyton JR, Dahlén GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
32. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687-702.
33. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
34. Riley WA, Barnes RW, Bond MG, Evans G, Chambless LE, Heiss G, for the ARIC Study Group. High resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. J Neuroimaging. 1991;1:168-172.
35. Bond MG, Barnes RW, Riley WA, Wilmoth SK, Chambless LE, Howard G, Owens B. High resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities (ARIC) Study. J Neuroimaging. 1991;1:68-73.
36. Xin-de W. Study on atherosclerosis of extracranial portion of carotid artery system in healthy persons. Chin Med J. 1989;102:441-444.
37. Tell GS, Howard G, McKinney WM. Risk factors for site specific extracranial carotid artery plaque distribution as measured by B-mode ultrasound. J Clin Epidemiol. 1989;42:551-559.
38. Solberg LA, McGarry PA, Moossy J, Tejada C, Loken AC, Robertson WB, Donoso S. Distribution of cerebral atherosclerosis by geographic location, race, and sex. Lab Invest. 1968;18:604-612.
39. Dempster AP, Laird NM, Rubin DB. Maximum likelihood estimation from incomplete data via the EM algorithm (with discussion). J R Stat Soc. 1977;B39:1-38.
40. Gaubatz JW, Chad MV, Nava ML, Guyton JR, Morrisett JD. Isolation and characterization of the two major apoproteins in human lipoprotein(a). J Lipid Res. 1987;28:69-79.
41. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein(a): structural properties. J Biol Chem. 1983;258:4582-4589.
42. Chambless LE, McMahon RP, Brown SA, Patsch W, Heiss G, Shen YL. Short-term intraindividual variability in lipoprotein measurements: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1992;136:1069-1081.
43. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
44. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
45. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
46. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
47. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
48. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
49. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
50. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
51. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
52. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
53. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
54. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
55. National Heart, Lung, and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No, 9, Hemostasis Determinations; No. 10, Clinical Chemistry; No. 11, Sitting Blood Pressure; No. 12, Quality Assurance. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
56. +2 precipitation. Clin Chem. 1982;28:1574. Abstract.
57. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
58. SAS User's Guide: Statistics, v 6. 4th ed. Cary, NC: SAS Institute Inc; 1990.
59. Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods. 2nd ed. Boston, Mass: PWS-Kent Publishing Co; 1988.
60. Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD. Polymorphic forms of human apolipoprotein(a): inheritance and relationship of their molecular weights to plasma levels of lipoprotein(a). J Lipid Res. 1990;31:603-613.
61. Grinstead GF, Ellefson RD. Heterogeneity of lipoprotein(a) and apolipoprotein(a). Clin Chem. 1988;34:1036-1040.
62. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentrations and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499.
63. Wiklund O, Angelin B, Olofsson S-O, Eriksson M, Fager G, Berglund L, Bondjers G. Apolipoprotein(a) and ischemic heart disease in familial hypercholesterolemia. Lancet. 1990;335:1360-1363.
64. Ghilain J-M, Parfonry A, Kozyreff V, Heller FR. Lipoprotein(a), cholesterol, and coronary heart diseases. Lancet. 1988;2:963. Letter.
65. Houlston R, Quiney J, Mount J, Watts GF, Lewis B. Lipoprotein(a) and coronary heart disease in familial hypercholesterolemia. Lancet. 1988;2:405. Letter.
66. Widhalm K, Genser D. Increased Hpoprotein(a) levels in children with familial hypercholesterolemia. Lancet. 1988;2:1262. Letter.
67. Albers JJ, Cabana VG, Warnick GR, Hazzard WR. Lp(a) lipoprotein: relationship to sinking pre-β lipoprotein, hyperlipoproteinemia, and apolipoprotein B. Metabolism. 1975;24:1047-1054.
68. Noma A, Maeda S, Okuna M, Abe A, Muto Y. Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alphatocopheryl nicotinate. Atherosclerosis. 1990;84:213-217.
69. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
70. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.
71. Jürgens G, Ashy A, Zenker G. Raised serum lipoprotein during treatment with lovastatin. Lancet. 1989;1:911-912.
72. Berg Schmidt E, Klausen IC, Kristensen SD, Lervang H-H, Færgeman O, Dyerberg J. The effect of n-3 polyunsaturated fatty acids on Lp(a). Clin Chim Acta. 1991;198:271-278.
73. Gavish D, Azrolan N, Cundey K, Breslow JL. Fish oil reduces plasma Lp(a) levels and affects post prandial association of apo(a) with TG rich lipoproteins. Clin Res. 1990;38:250a. Abstract.
74. Cardoso GC, Posadas C, Orvananos OO, Peniche C, Zamora J, Aguilar R, Holguin JA, Raynaud AS, Morrisett JD, Guevara J Jr. Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein(a). Chem Phys Lipids. 1994;67/68:207-222.
75. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C and the ARIC Investigators. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC Study. Am J Epidemiol. 1991;134:250-256.
76. Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G. Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 1993;13:826-833.
77. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 1991;49:1063-1074.
78. Sandholzer C, Boerwinkle E, Sana N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992;89:1040-1046.
79. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993;13:1558-1566.
80. Sandholzer C, Hallman DM, Sana N, Sigurdsson G, Lackner C, Császár A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
81. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JA, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003.
82. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J. 1990;301:1248-1251.
83. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
84. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.